Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Postmastectomy Lymphedema in Breast Cancer Survivors: A Multicenter Real-World Cohort Study
- Design
- Retrospective cohort · 61630 participants · Unknown outcome
- Match to healthy normal-weight adults aged 55–75
- Different population[Auto] Participants had obesity/overweight (age/BMI not reported in abstract).
- Could weight loss explain it?
- Possibly[Auto] Participants had obesity and/or type 2 diabetes and the abstract does not separate direct drug effects from weight loss or glycaemic improvement.
- Study tier
- Preliminary[Auto] Not peer reviewed (preprint, abstract or registration). Early-warning only.
- Assessment
- Version 1 · automatic, not yet reviewed by a person · Sep 13, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75. This item has not been peer reviewed.
[Auto, unreviewed; last sentences of abstract] These findings are hypothesis-generating and support prospective studies evaluating metabolic and anti-inflammatory strategies for lymphedema prevention in breast cancer survivorship. <bold>Clinical trial number</bold> : Not Applicable </p>
01Findings
What the study reported
- Drugs
- Class unspecified
- Comparator
- no exposure
- Primary outcome
- Not extracted
- Effect
- Not extracted
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- Not extracted
- Limitations
- Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.
Who was studied
- Obesity status
- obesity/overweight present (all or most)
- Sample size
- 61630
Study quality details
- Study design
- Retrospective cohort
- Sample size
- 61630
- Randomization
- no
- Blinding
- not stated
- Comparator
- not stated
- Follow up duration
- not stated
- Outcome type
- unknown
- Replication
- not assessed (auto)
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- INDIRECT
- Statistical precision
- CI reported: 95% CI 0
- Risk of bias
- not assessed (auto)
- Funding conflicts
- unclear
- Peer review status
- no
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- None identified
- Sponsor role
- not reported in abstract
- Author conflicts
- not available in metadata
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
<title>Abstract</title> <p> <bold>Purpose</bold> Postmastectomy lymphedema is a chronic survivorship complication after breast cancer treatment, particularly among patients exposed to axillary surgery. Obesity and metabolic inflammation are recognized contributors to lymphedema risk. This study evaluated whether glucagon-like peptide-1 receptor agonist exposure was associated with lower incident postmastectomy lymphedema among breast cancer patients undergoing mastectomy and/or axillary procedures. <bold>Methods</bold> We performed a retrospective cohort study using deidentified electronic health record data from the TriNetX Research Network. Adult patients with breast cancer who underwent mastectomy, axillary lymphadenectomy, sentinel lymph node biopsy, or had acquired absence of breast/nipple were stratified by GLP-1 receptor agonist exposure versus no exposure. One-to-one propensity score matching was used to balance measured baseline characteristics. The primary outcome was incident postmastectomy lymphedema syndrome. Outcomes were assessed from 1 to 650 days after the index event using risk estimates, Kaplan–Meier analysis, and Cox proportional hazards models. <bold>Results</bold> After propensity score matching, 61,630 patients were included, with 30,815 patients in each cohort. Postmastectomy lymphedema occurred in 258 of 29,259 GLP-1 receptor agonist users and 779 of 30,237 non-users, corresponding to risks of 0.88% and 2.58%, respectively. GLP-1 receptor agonist exposure was associated with lower postmastectomy lymphedema risk in time-to-event analysis (hazard ratio 0.373, 95% CI 0.324–0.429; p < 0.001). The absolute risk difference was − 1.7%, with an estimated number needed to treat of 59. <bold>Conclusion</bold> In this large real-world breast cancer cohort, GLP-1 receptor agonist exposure was associated with lower coded postmastectomy lymphedema risk over 650 days of follow-up. These findings are hypothesis-generating and support prospective studies evaluating metabolic and anti-inflammatory strategies for lymphedema prevention in breast cancer survivorship. <bold>Clinical trial number</bold> : Not Applicable </p>
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| europepmc | Sep 13, 2026 | PPR:PPR1310711 first ingestion |